Semaglutide linked to lower dementia risk
Archived — this story has rotated out of today’s deck. It is kept here in full.
The gist
Semaglutide slowed a blood protein signature linked to future dementia risk in a SELECT trial analysis.
The drug showed 26% lower predicted dementia event rate, but this is not proof.
Background
Semaglutide, a GLP-1 receptor agonist used for diabetes and obesity, has been investigated for potential neuroprotective effects. A post hoc analysis of the SELECT trial data, presented in Alzheimer's & Dementia, found that semaglutide attenuated a proteomics-based dementia risk score in older adults with overweight or obesity and cardiovascular disease. The study suggests a possible link but does not prove causation.
How it unfolded
- Aug 10, 2026Study published showing semaglutide slowed blood protein signature linked to future dementia risk.
- Aug 11, 2026MedPage Today reports the findings as part of a roundup, noting it was a post hoc analysis of SELECT trial data.
- Aug 14, 2026Related article discusses GLP-1 receptor agonists' potential in Alzheimer's, noting direct disease-modifying benefit remains unproven.
Who’s saying what
- Researchers
- The study shows an association but does not prove semaglutide prevents dementia.
- Caution
- Findings are from a post hoc analysis and need confirmation in prospective trials.
Still unverified
The study is a post hoc analysis, not a randomized trial designed to test dementia outcomes; the link is not proven.